OPPM
BIB icon

Opus Point Partners Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Opus Point Partners Management’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-60,000
Closed -$3.3M – 51
2018
Q1 		$3.3M Buy
+60,000
New +$3.59M 6.48% 2
2017
Q3 		– Sell
-42,500
Closed -$2.27M – 64
2017
Q2 		$2.27M Buy
+42,500
New +$2.07M 2.08% 16

Other funds holding BIB

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HCM
Howard Capital Management Roswell, Georgia $6.11B AUM 33.56% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BA
BKS Advisors Southfield, Michigan $249M AUM 14.37% 1-Year Est. Return
BRC
Bell Rock Capital Rehoboth Beach, Delaware $81M AUM 9.85% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Opus Point Partners Management's BIB Position: Q3 2018 in Review

Opus Point Partners Management sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q3 2018, closing a stake of 93,805 shares — an estimated $5.37M sold.

Opus Point Partners Management first reported a position in BIB in Q4 2014 and held it in 14 quarters. The position peaked at $10.3M in Q1 2018. 41 funds tracked by Wall St. Rank hold BIB as of Q3 2018.

  • Opus Point Partners Management reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q3 2018 after selling out during the quarter.
  • Opus Point Partners Management sold 93,805 ProShares Ultra NASDAQ Biotechnology shares in Q3 2018, an estimated $5.37M.
  • Opus Point Partners Management first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2014 and held it in 14 quarters.
  • Opus Point Partners Management's ProShares Ultra NASDAQ Biotechnology position peaked at $10.3M in Q1 2018.
  • 41 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q3 2018.

Based on Opus Point Partners Management's 13F filing for Q3 2018, filed 14 Nov 2018.